Imaging the Norepinephrine Transporter in Neuroblastoma: a Comparison of [18F]-MFBG and 123I-MIBG
Overview
Authors
Affiliations
Purpose: The norepinephrine transporter (NET) is a critical regulator of catecholamine uptake in normal physiology and is expressed in neuroendocrine tumors like neuroblastoma. Although the norepinephrine analog, meta-iodobenzylguanidine (MIBG), is an established substrate for NET, (123)I/(131)I-MIBG has several clinical limitations for diagnostic imaging. In the current studies, we evaluated meta-[(18)F]-fluorobenzylguanidine ([(18)F]-MFBG) and compared it with (123)I-MIBG for imaging NET-expressing neuroblastomas.
Experimental Design: NET expression levels in neuroblastoma cell lines were determined by Western blot and (123)I-MIBG uptake assays. Five neuroblastoma cell lines and two xenografts (SK-N-BE(2)C and LAN1) expressing different levels of NET were used for comparative in vitro and in vivo uptake studies.
Results: The uptake of [(18)F]-MFBG in cells was specific and proportional to the expression level of NET. Although [(18)F]-MFBG had a 3-fold lower affinity for NET and an approximately 2-fold lower cell uptake in vitro compared with that of (123)I-MIBG, the in vivo imaging and tissue radioactivity concentration measurements demonstrated higher [(18)F]-MFBG xenograft uptake and tumor-to-normal organ ratios at 1 and 4 hours after injection. A comparison of 4 hours [(18)F]-MFBG PET (positron emission tomography) imaging with 24 hours (123)I-MIBG SPECT (single-photon emission computed tomography) imaging showed an approximately 3-fold higher tumor uptake of [(18)F]-MFBG, but slightly lower tumor-to-background ratios in mice.
Conclusions: [(18)F]-MFBG is a promising radiopharmaceutical for specifically imaging NET-expressing neuroblastomas, with fast pharmacokinetics and whole-body clearance. [(18)F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET expression, allows same day scintigraphy with a shorter image acquisition time, and has the potential for lower patient radiation exposure compared with (131)I/(123)I-MIBG.
PET reporter systems for the brain.
Nerella S, Michaelides M, Minamimoto T, Innis R, Pike V, Eldridge M Trends Neurosci. 2023; 46(11):941-952.
PMID: 37734962 PMC: 10592100. DOI: 10.1016/j.tins.2023.08.007.
Grand-Guillaume J, Mansi R, Gaonkar R, Zanger S, Fani M, Eugster P J Transl Med. 2023; 21(1):604.
PMID: 37679770 PMC: 10485979. DOI: 10.1186/s12967-023-04466-z.
[F]MFBG PET/CT outperforming [I]MIBG SPECT/CT in the evaluation of neuroblastoma.
Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J Eur J Nucl Med Mol Imaging. 2023; 50(10):3097-3106.
PMID: 37160439 DOI: 10.1007/s00259-023-06221-4.
Badan M, Piciu D Acta Endocrinol (Buchar). 2023; 18(4):523-530.
PMID: 37152876 PMC: 10162825. DOI: 10.4183/aeb.2022.523.
The Impact of PET/CT on Paediatric Oncology.
Brink A, Hlongwa K, More S Diagnostics (Basel). 2023; 13(2).
PMID: 36673002 PMC: 9857884. DOI: 10.3390/diagnostics13020192.